Life Sciences Regulatory Compliance in South America 2026

On February 13, 2026, ANVISA published Normative Instruction 426, forcing every medical device holder in Brazil to start feeding a new UDI database, SIUD, on a risk-class schedule that began March 1, 2026. Five weeks later, on March 19, 2026, Chile's Ministry of Health published Exempt Decree 25, pulling 39 new device categories, including software as a medical device, into mandatory sanitary control for the first time. Neither agency coordinated with the other, and neither timeline lines up with what Colombia's INVIMA or Mexico's COFEPRIS did in the same quarter.

That is the defining trait of life sciences compliance in South America right now: five agencies, five reform tracks, no shared calendar. Brazil is closing a two decade old framework with a UDI mandate. Colombia is rewriting its rulebook from scratch. Mexico opened a fast lane for devices already cleared abroad. Argentina swapped pre-market review for sworn declarations on low risk imports. Chile just tripled the device categories under sanitary control. A manufacturer selling the same catheter or diagnostic kit across all five markets is tracking five different clocks in the same twelve months.

Pharmaceutical regulation is moving on a separate, slower track. Brazil's clinical trial rulebook, RDC 945/2024, has been fully binding since late 2024, while Chile's long promised drug pricing and generics law, known as Farmacos II, collapsed in its Comision Mixta on July 2, 2025 after more than a decade in Congress, with lawmakers now drafting a third attempt from scratch.

Which agencies actually drive life sciences enforcement in South America?

Five national regulators, each with its own device and drug tracks: ANVISA in Brazil, INVIMA in Colombia, COFEPRIS in Mexico, ANMAT in Argentina and the ISP in Chile. None of them answer to a regional body. There is no Andean or Mercosur equivalent of the EU's MDR that binds all five at once, so a change at ANVISA has zero automatic effect on what INVIMA requires next door. Companies that assume Latin America is one regulatory zone consistently miss country specific filings, because each agency publishes its own gazette, on its own schedule, in its own format.

What the five do share is a direction: all have spent 2025 and 2026 aligning device rules with IMDRF common data elements and recognizing at least some foreign approvals, through Brazil's UDI harmonization, Colombia's planned EU MDR alignment, Mexico's equivalency route, Argentina's reference country recognition, or Chile's international standards references inside Decree 25.

What changed for medical device registration in Brazil in 2026?

The registration framework itself, RDC 751/2022, has not changed since it replaced the 2001 rule in March 2023. What changed is traceability. Normative Instruction 426/2026, published February 13 and in force since March 1, 2026, operationalizes the Unique Device Identification requirement under RDC 591/2021: registration holders must transmit UDI-DI data to the SIUD database before a device reaches the Brazilian market, correct any error within 60 calendar days, and inactivate the identifier within 30 days once a product is discontinued or its authorization lapses. Compulsory transmission deadlines follow the risk class schedule set in RDC 591/2021's Article 15, so higher risk classes face the earliest cutoffs.

Class III and IV devices still go through full ANVISA registration, valid for ten years and renewable, while Class I and II devices use the lighter notification pathway with authorizations that do not expire outright. What matters for 2026 planning is procedural, not classificatory: a company can hold a perfectly valid registro and still fall out of compliance if its UDI-DI feed into SIUD is late or inaccurate.

How is Colombia rewriting a twenty year old device regime?

INVIMA is replacing Decreto 4725 of 2005 and Decreto 3770 of 2004 with a single new regime, and the draft is far along. The proposed text runs 16 chapters and roughly 180 articles, splits commercialization authorization into three tiers, notificacion sanitaria for low and moderate risk devices, registro sanitario for high and very high risk devices, and permiso de comercializacion for specially controlled biomedical equipment, and replaces the fixed ten year registration term with indefinite validity, subject to INVIMA's ongoing power to suspend, recall or cancel. The draft formally recognizes ISO 13485 as the accepted GMP standard and folds in-vitro diagnostics into the same framework for the first time, following INVIMA's presentation of the plan at the IMDRF meeting in March 2026.

The draft cleared its national consultation phase and was notified to the World Trade Organization on May 18, 2026, opening an international public comment window that closes July 17, 2026. Manufacturers, industry associations and importers have until that date to file technical comments through the WTO platform before INVIMA finalizes the decree. Separately, companies holding Class IIa devices registered before February 2024 had to complete UDI-DI compliance by February 9, 2026, a deadline that has already passed and left non-compliant registrations exposed to a market withdrawal risk.

Why did Mexico's COFEPRIS reform change cross border filing strategy?

Because it created a genuine shortcut for devices that already cleared a recognized foreign authority. COFEPRIS's Abbreviated Regulatory Pathway, Procedure Code COFEPRIS-04-050, took effect September 1, 2025 and became fully operational in early 2026. It lets a manufacturer holding a current, unconditional approval from the FDA, Health Canada, Japan's PMDA, the UK's MHRA, Australia's TGA, Brazil's ANVISA or an EU CE marking body request a Mexican registration decision within 30 business days, provided the device is identical in design, formulation, intended use and manufacturing process to the version already approved abroad. Conditional, emergency or accelerated foreign approvals do not qualify. A January 2026 reform to the renewal rules also extended validity for subsequent renewals from five years to up to ten, cutting recurring administrative load for products already on the market. Foreign manufacturers still need a Mexico Registration Holder to file on their behalf.

What does Argentina's sworn declaration system change for importers?

It removes the pre-market technical review for a defined slice of low risk products and replaces it with a signed statement backed by foreign equivalence. ANMAT's Disposicion 236/2026, published February 6, 2026 and regulating Decreto 892/2025, lets importers bring in Class I and II medical devices and Class A and B in-vitro diagnostics that do not require cold chain by filing a sworn declaration, DDJJ, through the Helena digital platform, instead of submitting the product for local technical evaluation. The declaration must be backed by a valid Certificate of Free Sale, no older than 24 months, or equivalent documentation from a reference country: the United States, the United Kingdom, Japan, Australia, Israel or an EU or EFTA member state.

The tradeoff is enforcement timing, not enforcement intensity. ANMAT shifted from pre-market technical review to strengthened post-market surveillance, and importers who cannot produce the underlying reference country documentation on request risk having their declaration invalidated retroactively. Argentina also eliminated the Certificate of Import of Used Goods requirement under a separate measure, Disposicion 224/2026, continuing the same deregulation logic.

Is pharmaceutical regulation converging as fast as medical device regulation?

No, and Chile is the clearest example of the gap. While the ISP's Decree 25 modernized device oversight in a single step, Chile's pharmaceutical pricing and generics reform, informally called Farmacos II, spent more than a decade in Congress before its Comision Mixta rejected reopening debate on July 2, 2025, sending the bill to the floor with no political backing. Lawmakers on both sides have since said they intend to abandon that text and draft a fresh Farmacos III bill built around the provisions that did have consensus, including a ban on drug advertising and mandatory dispensing by International Nonproprietary Name, but no new bill has been formally introduced as of mid-2026.

Brazil shows the opposite pattern on the drug side. RDC 945/2024 has governed clinical trials for marketing authorization purposes since November 29, 2024, requiring sponsors to file a Clinical Medicinal Product Development Dossier and report fatal or life threatening suspected unexpected serious adverse reactions to ANVISA's VigiMed system within 7 calendar days, and other SUSARs within 15 calendar days. ANVISA commits to evaluating a properly filed dossier within 90 business days, a concrete service standard most of the region's drug regulators have not published for their own queues.

How should a compliance team track five regulators without missing a filing?

Watching this manually means reading Brazil's Diario Oficial da Uniao, Colombia's WTO notification portal, Mexico's Diario Oficial de la Federacion, Argentina's Boletin Oficial and Chile's Diario Oficial in parallel, then translating each agency's own vocabulary, registro sanitario is not the same procedure in Bogota as in Santiago, into one compliance calendar. That is the workload per jurisdiction monitoring is built to absorb: watching ANVISA, INVIMA, COFEPRIS, ANMAT and the ISP at the source, and flagging the specific resolucion, decreto or instrucao normativa that touches a tracked device or drug category before the comment window or compliance deadline closes.

For teams that need a sourced answer inside an existing workflow rather than a new dashboard tab, the same tier-0 material is reachable through the MCP, so an AI assistant already in daily use can confirm, for instance, the exact date Colombia's WTO comment window closes, without a compliance officer first verifying whether the source is current. The AI stays a regulatory companion in that exchange, not a substitute for the officer who signs the filing, it just gets the sourced fact into their hands fast enough to act on it.

What should a life sciences compliance team do next

Build a five country matrix now, not after the next gazette notice: for each jurisdiction, log the instrument, the pathway, the agency and the next hard date, because none of these five reforms share a timeline. Colombia's July 17, 2026 WTO comment deadline is the nearest fixed date; missing it means losing the chance to shape a rulebook that will govern every device filed there for years. Brazil's UDI obligations keep expanding by risk class through 2027, and Chile's 24 and 36 month conformity windows under Decree 25 are already counting down from March 2026.

Obsidian's plans are built around exactly this kind of multi jurisdiction life sciences tracking, official source by official source, so the next INVIMA decree or ANMAT disposicion that matters reaches the compliance team before the comment window closes, not after.